Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 6/20 | 0.40 |
| ▸ | CDK8 | P49336 | 6/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537539 | 1.00 | NAMPT (0.42) | NAMPTCYP17A1RAB9ACCNCCDK8 | |
| SCHEMBL3543792 | 0.90 | NAMPT (0.42) | NAMPTCYP17A1RAB9ACCNCCDK8 | |
| SCHEMBL3543797 | 0.90 | NAMPT (0.42) | NAMPTCYP17A1RAB9ACCNCCDK8 | |
| SCHEMBL4075130 | 0.89 | CCNC (0.46) | NAMPTCYP17A1RAB9ACCNCCDK8 | |
| SCHEMBL29957148 | 0.84 | CYP17A1 (0.47) | NAMPTCYP17A1RAB9AATRMETAP1 | |
| SCHEMBL1020140 | 0.84 | CYP17A1 (0.47) | NAMPTCYP17A1RAB9AATRMETAP1 | |
| SCHEMBL16816111 | 0.81 | CA1 (0.45) | METAP1BRD9 | |
| SCHEMBL8953420 | 0.81 | CA1 (0.45) | METAP1BRD9 | |
| SCHEMBL4725743 | 0.81 | NAMPT (0.43) | NAMPTCYP17A1RAB9AATRMETAP1 | |
| SCHEMBL14291975 | 0.80 | CYP17A1 (0.42) | NAMPTCYP17A1RAB9AATRMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198282-B2 | Substituted azaquinazolines having an antiviral action | AICURIS GMBH & CO. KG (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7662822-B2 | Substituted azaquinazolines having an antiviral action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | NAMPT 1559/4885CYP17A1 4692/4885RAB9A 1869/4885 |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | EIF2AK2, TPMT, IRF3 | NAMPT 445/4885CYP17A1 4482/4885RAB9A 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.